510(k) · Cleared
ClearedIbl C1Q-Cic Cia Test
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Ibl GmbH · DAK Complement C1q, Antigen, Antiserum, Control
Cleared on Aug 29, 2003 after a 38-day review. FDA’s file for it is a 510(k) statement, which names no predicate.
- Decided
- Aug 29, 2003
- Review
- 38 days
- Class
- Class II
- Product code
- DAK
- Recalls
- None
- Predicates
- 0
FDA’s file for it is a 510(k) statement, which names no predicate.
Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in DAK? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against?
FDA’s file for it is a 510(k) statement, which names no predicate.
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
How does its category compare?
All DAK devicesDAK Complement C1q, Antigen, Antiserum, Control: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · DAK
FDA has decided no DAK device since 2007.
Median 510(k) review, days · DAK
Too few DAK 510(k)s in any year since 2007 to give a median.
Recalls per year · DAK
1in 2009
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · DAK
No MAUDE report names DAK since 2007.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 1 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 0 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The IBL Clq-CIC test is a quantitative enzyme immunoassay for the in vitro
diagnostic detection of circulating immune complex that bind C1q in human serum.
The measurement is performed as an aid in the diagnosis of various autoimmune
and other CIC related diseases. Levels of these complexes are one indicator in a
multi-factorial diagnostic regime.
Indications for use as stated in the FDA 510(k) statement.
https://510kreport.com/device/K032254 · printed Nov 3, 2026
Cite this page
510(k) Report. “K032254: Ibl C1Q-Cic Cia Test.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K032254
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Page last updated Nov 3, 2026